Efficacy of Monoclonal Neutralizing Antibody AZD 7442 (Tixagevimab-Cilgavimab for prevention of COVID-19 among cancer patients: Double blinded Randomized placebo Controlled Trial (ProvMAB Trial)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220901002

Enrollment

300

Registered

2022-09-01

Start date

2022-08-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The monoclonal antibody neutralizes the potency of AZD7442 can protect cancer patients to Coronarvirus 2019 infection Coronavirus disease , Monoclonal Neutralizing Antibody AZD7442 (Tixagevimab- Cilgavimab),covid-19 vaccine

Interventions

Injection Monoclonal antibody,NSS injection

Experimental Drug,Placebo Comparator Drug

Monoclonal antibody,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Low-risk patients or high-risk groups aged 18 years and over. 2. Weight greater than or equal to 40 kg. 3. Patients with Hematologic malignancy, breast cancer, lung cancer and colon cancer. who are receiving cancer treatment or have been treated for cancer within 6 months from the date of study (by assessing survival for more than 6 months). People who have received at least 3 doses of Covid-19 vaccine and received the latest dose of vaccine for more than 2 weeks and not more than 3 months. 5. Understand Thai language and be able to communicate with the researcher to assess side effects from treatment. Able to use communication technology equipment 6. Can be monitored 7. Consent and sign to participate in the research

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. Infected with Coronavirus 2019 within 3 months before participating in the research. 3. Has hepatic disease (child C) or end-stage renal disease (ESRD not on hemodialysis or not on hemodialysis at least twice a week). 4. Metastatic or terminal cancer (by assessing survival time less than 3 months) 5. Patients who are bedridden and unable to be treated are outpatients. 6. Previously received other neutralizing monoclonal antibody drugs within 60 days. 7. People who have had an allergic reaction to Tixagevimab/Cilgavimab. 8. People who have received the latest dose of Covid-19 vaccine for more than 3 months.

Design outcomes

Primary

Measure	Time frame
Symptomatic COVID infection 180 days percent	—

Secondary

Measure	Time frame
Immunity antibody 180 days percent	—

Countries

Thailand

Contacts

Public ContactChulabhorn Hospital

Chulabhorn hospital

EC.CRA@cra.ac.th025766000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026